NeurAxis, Inc. NRXS

Company Overview

NeurAxis, Inc. is a U.S.-based medical technology company focused on neuromodulation therapies for chronic and debilitating conditions, primarily in pediatric and adolescent patient populations. The company operates in the healthcare and medical device industries and is best known for commercializing the IB-Stim device, a percutaneous electrical nerve field stimulation (PENFS) therapy cleared by the U.S. Food and Drug Administration for functional abdominal pain associated with irritable bowel syndrome (IBS) in patients aged 8 to 21 years. Revenue has historically been driven primarily through sales of the IB-Stim device and related treatment procedures to healthcare providers specializing in gastroenterology and pediatric care.

NeurAxis originated from technology developed to address disorders influenced by the autonomic nervous system and has evolved into a focused neuromodulation company targeting conditions with limited pharmaceutical treatment alternatives. The company has positioned itself within a specialized segment of non-drug pain management and gastrointestinal treatment, emphasizing minimally invasive therapy and physician-supervised outpatient use. Its strategic differentiation is tied to FDA-cleared technology, clinical validation in pediatric gastrointestinal disorders, and reimbursement expansion efforts with commercial insurers and government healthcare programs.

Business Operations

NeurAxis generates revenue primarily through commercialization of its IB-Stim neuromodulation platform within the United States. The company’s core operations center on device manufacturing oversight, commercialization, physician training, reimbursement support, and clinical engagement with pediatric gastroenterology networks. The IB-Stim system delivers electrical stimulation through branches of cranial nerves in the ear and is prescribed as part of a multi-week treatment protocol. Public filings and company disclosures indicate that operations are concentrated mainly in the U.S. healthcare market, with an emphasis on expanding physician adoption and payer coverage.

The company controls intellectual property and regulatory assets associated with the PENFS platform and related treatment methodologies. NeurAxis has also pursued clinical studies and healthcare partnerships intended to broaden awareness among hospitals, pediatric specialists, and gastrointestinal treatment centers. Public disclosures reference collaborations with healthcare providers and reimbursement stakeholders rather than large-scale international joint ventures. Data regarding material overseas operating subsidiaries or major foreign revenue streams is inconclusive based on available public sources.

Strategic Position & Investments

NeurAxis has focused its strategic direction on expanding utilization of IB-Stim through broader reimbursement coverage, increased physician adoption, and clinical validation initiatives. The company has emphasized growth through evidence-based medicine, including publication and support of clinical data related to functional gastrointestinal disorders and pediatric pain management. Strategic priorities disclosed in public filings include increasing insurance payer acceptance, scaling commercial infrastructure, and evaluating additional therapeutic applications for PENFS technology.

The company has also explored opportunities to extend neuromodulation applications beyond IBS-related abdominal pain into adjacent disorders involving the gut-brain axis and autonomic nervous system regulation. While NeurAxis remains comparatively small relative to major medical device manufacturers, its positioning in pediatric functional gastrointestinal treatment represents a differentiated niche within non-opioid and non-pharmaceutical therapy markets. Publicly available information does not indicate major transformative acquisitions or large portfolio holdings as of recent filings, though the company continues to invest in commercialization and clinical expansion initiatives tied to its proprietary technology platform.

Geographic Footprint

NeurAxis is headquartered in the United States, with principal operations centered in the domestic healthcare market. Its commercial activities are primarily directed toward U.S.-based pediatric gastroenterology practices, hospitals, and specialty clinics. The company’s regulatory and reimbursement strategy has focused largely on the U.S. medical system, including engagement with private insurers and government healthcare programs.

Although the company’s technology may have relevance in broader international neuromodulation markets, publicly available disclosures indicate that the majority of operational and commercial activity remains concentrated in North America. Data regarding meaningful revenue exposure or established operational infrastructure in Europe, Asia-Pacific, or other global regions is inconclusive based on available public sources.

Leadership & Governance

NeurAxis leadership has emphasized commercialization discipline, clinical evidence generation, and reimbursement expansion as central elements of the company’s growth strategy. Public statements and investor materials have highlighted a focus on building physician adoption while strengthening payer relationships to improve treatment accessibility. Governance and executive oversight are aligned with the company’s position as a publicly traded medical technology company listed on the NYSE American under the ticker NRXS.

Key executives and leadership figures include:

• Brian Carrico – Chief Executive Officer
• Wayne Keathley – Chief Financial Officer
• Jennifer Piel – Vice President of Clinical and Regulatory Affairs

Public company governance is supported through board oversight and reporting obligations associated with filings such as SEC Form 10-K, SEC Form 10-Q, and other regulatory disclosures. Information regarding founders and certain historical executive roles varies across public disclosures; where inconsistencies exist, data is inconclusive based on available public sources.